New pill combo shows promise in advanced cancer trial
NCT ID NCT05929235
First seen Jan 31, 2026 · Last updated May 22, 2026 · Updated 21 times
Summary
This early-stage study tests a new daily pill, FX-909, alone or with another drug (pembrolizumab), in people with advanced solid tumors, including bladder cancer. The main goals are to check safety and find the best dose. About 120 adults will take part, with regular blood tests and scans to monitor effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED UROTHELIAL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Houston Methodist Cockrell Center for Advanced Therapeutics
RECRUITINGHouston, Texas, 77030, United States
Contact
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Mass General Cancer Center
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Memorial Slone Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sarah Cannon Research Institute
RECRUITINGNashville, Tennessee, 37203, United States
Contact
Contact Phone: •••-•••-••••
-
Sylvester Comprehensive Cancer Center, University of Miami
RECRUITINGMiami, Florida, 33136, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Cleveland Clinic Foundation
RECRUITINGCleveland, Ohio, 44195, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The University of Chicago Medicine
RECRUITINGChicago, Illinois, 60637, United States
Contact
-
UCSF Helen Diller Family Comprehensive Cancer Center
RECRUITINGSan Francisco, California, 94158, United States
Contact
-
UNC Lineberger Comprehensive Cancer Center
RECRUITINGChapel Hill, North Carolina, 27514, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Yale Cancer Center
RECRUITINGNew Haven, Connecticut, 06519, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.